CoChat
Sign Up
Cited by 172Esophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesPhotodynamic Therapy Research Studies

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus

Peters, Femke P., Kara, Mohammed A., Rosmolen, Wilda D., Aalders, Maurice C.G., ten Kate, Fiebo J.W., Bultje, Bert C., Krishnadath, Kausilia K., Fockens, Paul, van Lanschot, Jan J.B., van Deventer, Sander J.H., Bergman, Jacques J.G.H.M.·2005·Gastrointestinal Endoscopy
DOI 10.1016/s0016-5107(05)00063-5
Open this paper in CoChat — free account

Abstract

Background The aim of this study was to prospectively evaluate endoscopic resection (ER) combined with photodynamic therapy (PDT) for the treatment of selected patients with early neoplasia in Barrett's esophagus. Methods Patients with Barrett's esophagus and neoplastic lesions <2 cm in diameter and no sign of submucosal infiltration, positive lymph nodes, or distant metastasis underwent diagnostic ER (cap technique). Patients with a T1sm tumor in the resection specimen were referred for surgery; those with a T1m or a less invasive tumor underwent additional endoscopic therapy (ER, PDT, and/or argon plasma coagulation [APC]), or they were followed. PDT was performed with 5-aminolevulinic acid and a light dose of 100 J/cm 2 at lambda = 632 nm. Results Thirty-three patients underwent diagnostic ER. Endoscopic treatment was not performed in 5 patients, who underwent surgery (4 T1sm; 1, patient preference). Five patients were immediately entered into a follow-up protocol, and 23 received additional endoscopic treatment (13 additional ER, 19 PDT, 3 APC). Endoscopic treatment was successful in 26/28 patients; no severe complication was observed. During follow-up (median 19 months, range 13-24 months), 5/26 patients had a recurrence of high-grade dysplasia: all were successfully re-treated with ER. At the end of follow-up, 26/33 originally enrolled patients (79%) and 26/28 endoscopically treated patients (93%) were in local remission. Conclusions Endoscopic therapy is safe and effective for selected patients with early stage neoplasia in Barrett's esophagus.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0016-5107(05)00063-5

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALA-PDT was shown to be more effective in eradicating high-grade dysplasia than in treatment of early esophagus cancer.

    “ALA-PDT was shown to be more effective in eradicating high-grade dysplasia than in treatment of early esophagus cancer [124,125].”

    From Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer (2011) · cites this paper as [125]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Behrens, 2003, Curative endoscopic therapy of early cancer and high-grade dysplasia in Barrett's esophagus can reduce the risk of recurrent carcinomas, Gastroenterology, 124
  2. Hino, 2003, A new material to aid endoscopic mucosal resection (EMR), Gastrointest Endosc, 57
  3. Inoue, 2003, A novel procedure of en bloc EMR using triangle-tipped knife, Gastrointest Endosc, 57
  4. Rajan, 2003, Widespread endoscopic mucosal resection (WEMR) of the esophagus in a porcine model with a prototype endoscopic cap device, Gastrointest Endosc, 57

Cited by

Sorted by citations

Related

Metadata

Authors
Peters, F. P., Kara, M. A., Rosmolen, W. D., Aalders, M. C. G., ten Kate, F. J. W., Bultje, B. C., Krishnadath, K. K., Fockens, P., van Lanschot, J. J. B., van Deventer, S. J. H., & Bergman, J. J. G. H. M.
Affiliations
Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Bergman, Jacques J.G.H.M.
ORCID
Venue
Gastrointestinal Endoscopy
Publisher
Elsevier BV
Published
2005-04
Volume
61
Issue
4
Pages
506-514
ISSN
0016-5107 (ISSN-L)
DOI
10.1016/s0016-5107(05)00063-5
OpenAlex
W2062340807
Cited by
172
References
48
Citations by year
2025: 1 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 10 · 2015: 13 · 2014: 8 · 2013: 13 · 2012: 12
FWCI
15.47
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Gastrointestinal Endoscopy (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
Keywords
Barrett's esophagus, high-grade dysplasia, early esophageal cancer, endoscopic resection, photodynamic therapy, argon plasma coagulation, 5-aminolevulinic acid, recurrence, endoscopic treatment
MeSH terms
Aged, Argon, Barrett Esophagus, Esophageal Neoplasms, Esophagoscopy, Female, Humans, Male, Middle Aged, Neoplasm Staging, Photochemotherapy, Prospective Studies, Treatment Outcome, Laser Coagulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review